Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study
Top Cited Papers
- 1 December 2007
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (34) , 5410-5417
- https://doi.org/10.1200/jco.2007.11.7960
Abstract
Purpose This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibi...Keywords
This publication has 19 references indexed in Scilit:
- A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced CancerClinical Cancer Research, 2006
- Hsp90: A Novel Target for Cancer TherapyCurrent Topics in Medicinal Chemistry, 2006
- Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft ModelsClinical Cancer Research, 2005
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced CancersClinical Cancer Research, 2005
- 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma modelsAnti-Cancer Drugs, 2004
- Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Oncogene, 2002
- HSP90 as a new therapeutic target for cancer therapy: the story unfoldsExpert Opinion on Biological Therapy, 2002
- Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90Proceedings of the National Academy of Sciences, 1996
- Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.Proceedings of the National Academy of Sciences, 1994